Loading...
Please wait, while we are loading the content...
Similar Documents
Review Platelet glycoprotein IIb/IIIa receptor blockade in coronary (2001)
| Content Provider | CiteSeerX |
|---|---|
| Author | Salam, Amar M. Suwaidi, Jassim Al |
| Abstract | Glycoprotein IIb/IIIa inhibitors represent a new promising class of antiplatelet medications. Their use in acute coronary syndromes and for patients undergoing percutaneous coronary intervention has been the subject of a number of large controlled trials using both the intravenous and the oral forms. In this review, we present a systematic overview of these trials. Keywords coronary artery disease, glycoprotein IIb/IIIa inhibitors, myocardial infarction, percutaneous coronary interventions Platelets play a pivotal role in acute coronary syndromes [1,2]. Plaque rupture exposes highly thrombogenic components that induce platelet activation and initiate coagulation cascade. Platelet activation involves a conformational change in the membrane glycoproteins (GP) that are receptors for adhesive proteins [3]. The recent development of a new class of drugs that allow direct inhibition of platelet GP IIb/IIIa receptors, the ‘final common pathway ’ of platelet activation, has raised the possibility that these potent agents may reduce thrombotic complications after percutaneous coronary interventions or in acute coronary syndromes [4]. In the following review, we summarize the trials conducted to evaluate the use of GP IIb/IIIa inhibitors in these clinical settings, and discuss issues of efficacy and safety. Intravenous GP IIb/IIIa antagonists Four intravenous GP IIb/IIIa antagonists have been investigated: abciximab (c7E3 Fab), eptifibatide (Integrilin), tirofiban (Aggrastat), and lamifiban (Ro 44-9883) (Table 1). Percutaneous coronary interventions The role of periprocedural intravenous GP IIb/IIIa inhibition in percutaneous coronary revascularization was established in nine placebo-controlled randomized trials and one comparative trial enrolling, in total, over 24,000 |
| File Format | |
| Publisher Date | 2001-01-01 |
| Access Restriction | Open |
| Subject Keyword | Keywords Coronary Artery Disease Comparative Trial Enrolling Antiplatelet Medication Clinical Setting Intravenous Gp Iib Iiia Antagonist Oral Form Plaque Rupture Following Review Final Common Pathway Thrombotic Complication Thrombogenic Component Intravenous Gp Iib Iiia C7e3 Fab Gp Iib Iiia Inhibitor Pivotal Role Acute Coronary Syndrome Glycoprotein Iib Iiia Inhibitor Platelet Gp Iib Iiia Receptor Membrane Glycoprotein Initiate Coagulation Cascade Recent Development Percutaneous Coronary Revascularization Systematic Overview Discus Issue Myocardial Infarction Platelet Activation Conformational Change Adhesive Protein Percutaneous Coronary Intervention Platelet Direct Inhibition Potent Agent Percutaneous Coronary Intervention New Promising Class |
| Content Type | Text |
